Live price temporarily unavailable.
Whitehawk Therapeutics (WHWK) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $20.2M | $0 | $14.0M | $14.0M | $15.2M | $24.4M | $26.0M | $7.14M |
| Growth (year over year) | — | — | — | −100.0% | — | 0.0% | +8.7% | +60.1% | +6.7% | −72.5% |
| Gross profit | — | — | — | — | — | $14.0M | $13.9M | $21.5M | $23.0M | $6.38M |
| Gross margin | — | — | — | — | — | 100.0% | 91.2% | 88.5% | 88.4% | 89.4% |
| Operating income | −$16.6M | −$21.4M | −$11.2M | −$24.4M | −$2.55M | −$111.2M | −$62.7M | −$71.9M | −$67.5M | −$114.4M |
| Operating margin | — | — | −55.5% | — | −18.2% | −794.4% | −411.9% | −295.4% | −259.6% | −1601.1% |
| Net income | −$17.0M | −$21.4M | −$10.4M | −$23.3M | −$3.48M | −$110.1M | −$60.5M | −$65.8M | −$63.7M | −$20.6M |
| Net margin | — | — | −51.6% | — | −24.8% | −786.4% | −397.7% | −270.0% | −245.1% | −288.3% |
| EPS (diluted) | −$24.52 | −$1.03 | −$0.31 | −$0.57 | −$1.76 | −$12.41 | −$2.69 | −$2.44 | −$2.36 | −$0.33 |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.61M | $20.3M | $62.6M | $38.5M | $4.46M | $149.0M | $39.0M | $62.9M | $28.7M | $37.6M |
| Total assets | $2.40M | $21.0M | $64.1M | $39.9M | $18.8M | $157.9M | $184.2M | $132.4M | $70.3M | $150.8M |
| Total liabilities | $88.6M | $3.59M | $5.46M | $3.40M | $31.3M | $21.5M | $25.9M | $27.2M | $17.8M | $14.5M |
| Shareholders' equity | −$86.2M | $17.4M | $58.7M | −$9.09M | −$12.4M | $136.4M | $158.4M | $105.2M | $52.5M | $136.3M |
| Cash flow | ||||||||||
| Operating cash flow | −$24.5K | −$18.9M | −$5.81M | −$23.9M | −$12.7M | −$22.4M | −$49.6M | −$59.7M | −$59.5M | −$97.4M |
| Capital expenditure | $113.3K | $8.90K | $37.9K | $237.0K | $19.0K | $46.0K | $444.0K | $3.97M | $1.65M | $552.0K |
| Free cash flow | −$137.8K | −$18.9M | −$5.85M | −$24.1M | −$12.7M | −$22.5M | −$50.1M | −$63.6M | −$61.2M | −$98.0M |
| Dividends paid | — | — | — | — | — | $4.41M | $0 | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.21M | $7.24M | $7.14M | $0 | $0 | — | $0 | $0 |
| Growth (year over year) | +21.0% | +14.4% | +33.5% | −100.0% | −100.0% | — | −100.0% | — |
| Gross profit | $6.41M | $6.45M | $6.38M | $0 | $0 | — | $0 | $0 |
| Gross margin | 88.9% | 89.1% | 89.4% | — | — | — | — | — |
| Operating income | −$13.4M | −$18.9M | −$15.2M | −$54.7M | −$19.5M | — | −$23.5M | −$18.1M |
| Operating margin | −186.0% | −261.8% | −213.0% | — | — | — | — | — |
| Net income | −$12.5M | −$18.3M | $73.0M | −$52.6M | −$17.7M | — | −$22.2M | −$16.6M |
| Net margin | −174.0% | −252.4% | 1021.9% | — | — | — | — | — |
| EPS (diluted) | −$0.46 | −$0.68 | $1.83 | −$0.76 | −$0.26 | — | −$0.32 | −$0.20 |
| Balance sheet | ||||||||
| Cash and equivalents | $30.5M | $28.7M | $227.6M | $144.9M | $37.9M | $37.6M | $34.8M | $85.2M |
| Total assets | $85.7M | $70.3M | $234.0M | $180.8M | $167.0M | $150.8M | $127.2M | $194.0M |
| Total liabilities | $16.8M | $17.8M | $12.3M | $8.76M | $9.85M | $14.5M | $11.1M | $11.1M |
| Shareholders' equity | $68.9M | $52.5M | $221.7M | $172.1M | $157.2M | $136.3M | $116.2M | $182.9M |
| Cash flow | ||||||||
| Operating cash flow | −$15.7M | −$15.1M | −$11.9M | −$53.0M | −$15.4M | — | −$22.2M | −$14.5M |
| Capital expenditure | $188.0K | $186.0K | $551.0K | $1.00K | $0 | — | $0 | $0 |
| Free cash flow | −$15.9M | −$15.2M | −$12.4M | −$53.0M | −$15.4M | — | −$22.2M | −$14.5M |
From Whitehawk Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Whitehawk Therapeutics in our feed yet.